Aspira Women’s Health Appoints Three New Members to its Board of Directors
2023年5月10日 - 5:07AM
Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a
bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced it the appointment of three new independent directors:
Stefanie Cavanaugh, Jannie Herchuck, and Lynn O’Connor Vos.
“We are thrilled to welcome Stefanie, Jannie and Lynn to our
Board of Directors,” said Dr. Veronica Jordan, Chairwoman
of the Aspira Board of Directors. “Aspira has been through
tremendous change this past year, and attracting top talent is a
testament to the strength of the technology, strategy and potential
as a company. We look forward to their guidance as we continue to
grow and unlock the tremendous potential to improve the treatment
pathway for all women.”
Nicole Sandford, President and Chief Executive Officer
of Aspira Women’s Health said, “We warmly welcome our new
members to the Aspira Board of Directors. Stefanie, Jannie and Lynn
are very experienced and extraordinarily successful executives who
bring a passion for improving women’s lives. I look forward to
working closely with them as we move swiftly to the next level of
growth.”
Ms Stefanie Cavanaugh joins the Board as a seasoned executive
having been a senior financial executive for healthcare companies
for over 30 years. Ms. Cavanaugh currently serves as Chief
Financial Officer of Giving Home Health Care, an at-home healthcare
services company.
Ms. Jannie Herchuck served in various roles at Deloitte &
Touche since 1985 until her retirement as an audit partner in 2022.
Ms. Herchuck most recently served on the Deloitte LLP board of
directors leading strategic initiatives and practices.
Ms. Lynn O’Connor Vos is a healthcare CEO and Board Director
with experience across product launches, global marketing , digital
health, and M&A. She founded her own healthcare consultancy
firm after having served as interim CEO of Modular Medical, Inc.
She spent nearly 30 years as CEO of Greyhealth Group where she
built a global healthcare communications firm and worked on
launches for clients across the pharmaceutical, biotech, surgical
and diagnostic sectors.
About Aspira Women’s Health Inc.Aspira
Women’s Health Inc. is transforming women’s gynecological health
with the discovery, development, and commercialization of
innovative testing options for women of all races and ethnicities,
starting with ovarian cancer.
Our ovarian cancer risk assessment portfolio is marketed to
healthcare providers as OvaSuite. OvaWatchSM is a
non-invasive, blood-based test intended for use in the initial
clinical assessment of ovarian cancer risk in women with benign or
indeterminate adnexal masses for which surgical intervention may be
either premature or unnecessary. With a negative predictive value
(NPV) of 99%, OvaWatch allows physicians to confidently rule out
ovarian cancer malignancy and choose the appropriate clinical
management for the right patient at the right time.
Ova1Plus® combines our FDA-cleared products, Ova1® and
Overa®, to detect risk of ovarian malignancy in women with adnexal
masses planned for surgery.
EndoCheck™, Aspira’s first-of-its-kind non-invasive diagnostic
test for endometriosis, is currently in development. Visit our
website for more information
at www.aspirawh.com.
Forward-Looking StatementsThis
press release contains forward-looking statements, as defined in
the Private Securities Litigation Reform Act of 1995, including
statements regarding the planned launches of our serial monitoring
test and our EndoCheck diagnostic blood test by the end of 2023.
Forward-looking statements involve a number of risks and
uncertainties. Words such as “may,” “expects,” “intends,”
“anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,”
“should,” “continue,” “will,” “potential,” “projects” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions, including those described in the section entitled
“Risk Factors” in Aspira’s Annual Report on Form 10-K for the year
ended December 31, 2022. These risks include, but are not limited
to: our ability to continue as a going concern; our ability to
comply with Nasdaq’s continued listing requirements; impacts
resulting from potential changes to coverage of Ova1 through our
Medicare Administrative Carrier for Ova1; impacts resulting from or
relating to the COVID-19 pandemic and actions taken to contain it;
anticipated use of capital and its effects; our ability to increase
the volume of our product sales; failures by third-party payers to
reimburse for our products and services or changes to reimbursement
rates; our ability to continue developing existing technologies and
to develop, protect and promote our proprietary technologies; plans
to develop and perform laboratory developed tests; our ability to
comply with Food and Drug Administration (“FDA”) regulations that
relate to our products and to obtain any FDA clearance or approval
required to develop and commercialize medical devices; our ability
to develop and commercialize additional diagnostic products and
achieve market acceptance with respect to these products; our
ability to compete successfully; our ability to obtain any
regulatory approval required for our future diagnostic products; or
our suppliers’ ability to comply with FDA requirements for
production, marketing and post-market monitoring of our products;
our ability to maintain sufficient or acceptable supplies of
immunoassay kits from our suppliers; in the event that we succeed
in commercializing our products outside the United States, the
political, economic and other conditions affecting other countries;
changes in healthcare policy; our ability to comply with
environmental laws; our ability to comply with the additional laws
and regulations that apply to us in connection with the operation
of ASPiRA LABS; our ability to use our net operating loss
carryforwards; our ability to use intellectual property; our
ability to successfully defend our proprietary technology against
third parties; our ability to obtain licenses in the event a third
party successfully asserts proprietary rights; the liquidity and
trading volume of our common stock; material weaknesses in our
internal control over financial reporting; the concentration of
ownership of our common stock; our ability to retain key employees;
our ability to secure additional capital on acceptable terms to
execute our business plan; business interruptions; the
effectiveness and availability of our information systems; our
ability to integrate and achieve anticipated results from any
acquisitions or strategic alliances; future litigation against us,
including infringement of intellectual property and product
liability exposure; and additional costs that may be required to
make further improvements to our laboratory operations. The events
and circumstances reflected in Aspira’s forward-looking statements
may not be achieved or occur, and actual results could differ
materially from those projected in the forward-looking statements.
Aspira expressly disclaims any obligation to update, amend or
clarify any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by
law.
Investor Relations
Contact:Monique Kosse Managing DirectorLifeSci Advisors,
LLCTel: 212-915-3820
Aspira Womans Health (NASDAQ:AWH)
過去 株価チャート
から 8 2024 まで 9 2024
Aspira Womans Health (NASDAQ:AWH)
過去 株価チャート
から 9 2023 まで 9 2024